The Colorectal Cancer Therapeutics Market is projected to grow from USD 13.37 billion in 2025 to USD 19.95 billion by 2034, at a CAGR of 4.55%. Growth is driven by rising cases, immunotherapy innovation, and digital health integration. North America leads, while Asia-Pacific sees fastest expansion.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Colorectal Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Colorectal Cancer Therapeutics Market, by Therapy
8.1.1 Targeted Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. Colorectal Cancer Therapeutics Market, by Cancer Type
9.1.1. Colorectal Adenocarcinoma
9.1.1.1. Market Revenue and Forecast
9.1.2. Gastrointestinal Carcinoid Tumors
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. Colorectal Cancer Therapeutics Market, by Distribution Channel
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Therapy
11.1.2. Market Revenue and Forecast, by Cancer Type
11.1.3. Market Revenue and Forecast, by Distribution Channel
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Therapy
11.1.4.2. Market Revenue and Forecast, by Cancer Type
11.1.4.3. Market Revenue and Forecast, by Distribution Channel
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Therapy
11.1.5.2. Market Revenue and Forecast, by Cancer Type
11.1.5.3. Market Revenue and Forecast, by Distribution Channel
11.2. Europe
11.2.1. Market Revenue and Forecast, by Therapy
11.2.2. Market Revenue and Forecast, by Cancer Type
11.2.3. Market Revenue and Forecast, by Distribution Channel
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Therapy
11.2.4.2. Market Revenue and Forecast, by Cancer Type
11.2.4.3. Market Revenue and Forecast, by Distribution Channel
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Therapy
11.2.5.2. Market Revenue and Forecast, by Cancer Type
11.2.5.3. Market Revenue and Forecast, by Distribution Channel
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Therapy
11.2.6.2. Market Revenue and Forecast, by Cancer Type
11.2.6.3. Market Revenue and Forecast, by Distribution Channel
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Therapy
11.2.7.2. Market Revenue and Forecast, by Cancer Type
11.2.7.3. Market Revenue and Forecast, by Distribution Channel
11.3. APAC
11.3.1. Market Revenue and Forecast, by Therapy
11.3.2. Market Revenue and Forecast, by Cancer Type
11.3.3. Market Revenue and Forecast, by Distribution Channel
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Therapy
11.3.4.2. Market Revenue and Forecast, by Cancer Type
11.3.4.3. Market Revenue and Forecast, by Distribution Channel
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Therapy
11.3.5.2. Market Revenue and Forecast, by Cancer Type
11.3.5.3. Market Revenue and Forecast, by Distribution Channel
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Therapy
11.3.6.2. Market Revenue and Forecast, by Cancer Type
11.3.6.3. Market Revenue and Forecast, by Distribution Channel
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Therapy
11.3.7.2. Market Revenue and Forecast, by Cancer Type
11.3.7.3. Market Revenue and Forecast, by Distribution Channel
11.4. MEA
11.4.1. Market Revenue and Forecast, by Therapy
11.4.2. Market Revenue and Forecast, by Cancer Type
11.4.3. Market Revenue and Forecast, by Distribution Channel
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Therapy
11.4.4.2. Market Revenue and Forecast, by Cancer Type
11.4.4.3. Market Revenue and Forecast, by Distribution Channel
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Therapy
11.4.5.2. Market Revenue and Forecast, by Cancer Type
11.4.5.3. Market Revenue and Forecast, by Distribution Channel
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Therapy
11.4.6.2. Market Revenue and Forecast, by Cancer Type
11.4.6.3. Market Revenue and Forecast, by Distribution Channel
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Therapy
11.4.7.2. Market Revenue and Forecast, by Cancer Type
11.4.7.3. Market Revenue and Forecast, by Distribution Channel
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Therapy
11.5.2. Market Revenue and Forecast, by Cancer Type
11.5.3. Market Revenue and Forecast, by Distribution Channel
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Therapy
11.5.4.2. Market Revenue and Forecast, by Cancer Type
11.5.4.3. Market Revenue and Forecast, by Distribution Channel
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Therapy
11.5.5.2. Market Revenue and Forecast, by Cancer Type
11.5.5.3. Market Revenue and Forecast, by Distribution Channel
12.1. Bayer AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol Myers Squibb
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Genentech, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Ipsen Biopharmaceuticals, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck Sharp & Dohme Corp.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Regeneron Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Teva Pharmaceutical Industries Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description